InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,599.60
(
1.04%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.48
(
0.42%
)
Bitcoin
63,538.89
(
-0.73%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 325

Tuesday, 08/28/2018 1:17:50 PM

Tuesday, August 28, 2018 1:17:50 PM

Post# of 438
NITE is a clinical stage gene therapy company focusing on currently untreatable retinal diseases.

Commercialization of lead product is 2 - 3 years away.

Lead program is in Ph3. One year follow-up data is expected in 2020.

The second program is Retinitis Pigmentosa. Ph1/2 data will be read out at the 9/18 R&D day. Then, one year follow up data will be due H2/19.

Cash runway extends into 2020. But, there is some possibility of gaining capital thru foreign partnership(s).
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up